[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623318":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":39,"collaborators":7,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":7,"enrollmentInfo":50,"targetDuration":7,"studyType":53,"phases":7,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Pierre-Louis BLOT, MD","CONTACT","+331049956565","pierre-louis.blot@aphp.fr",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Benjamin Chousterman, MD PhD","+330149958518","benjamin.chousterman@aphp.fr",[19],{"facility":20,"status":21,"city":22,"state":7,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Hôpital Lariboisière","RECRUITING","Paris","75010","France","FR",{"type":27,"coordinates":28},"Point",[29,30],2.3488,48.85341,{"lat":30,"lon":29},[33,37],{"name":10,"role":11,"phone":34,"phoneExt":35,"email":36},"01 49 95 85 15","+33","pierre-louis-blot@aphp.fr",{"name":38,"role":11,"phone":7,"phoneExt":7,"email":17},"Benjamin CHOUSTERMAN, MD",{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100623318","study-of-the-immunological-pathophysiological-mechanisms-associated-with-acute-respiratory-distress-syndrome-100623318",false,"NCT07395076","Study of the Immunological Pathophysiological Mechanisms Associated With Acute Respiratory Distress Syndrome","IMMUNORESP2","Inclusion Criteria:\n\n* ARDS risk factors: bacterial or viral pneumonia, extrapulmonary infection, major trauma, transfusion, inhalation injury, or shock.\n* Pulmonary edema not explained by a cardiogenic cause or volume overload.\n* Onset of respiratory symptoms within \\\u003C7 days.\n* Bilateral pulmonary involvement on chest X-ray, CT scan, or ultrasound.\n* PaO₂\u002FFiO₂ ≤ 300 assessed with PEEP ≥ 5 cmH₂O.\n\nExclusion Criteria:\n\n* ARDS with intubation for more than 48 hours.\n* Contraindications to bronchoscopy: effective anticoagulation, dual antiplatelet therapy, thrombocytopenia \\\u003C50 G\u002FL.\n* Pre-existing immunodeficiency: active solid tumor or remission \\\u003C5 years, active hematologic malignancy or remission \\\u003C5 years, systemic disease (even without specific treatment), solid organ or bone marrow transplant, HIV infection with CD4 \\\u003C200\u002Fmm³.\n* Cardiac arrest with a poor prognosis (NSE \\>60, malignant EEG, diffuse ischemia on imaging, loss of trunk reflexes).\n* Patients \\\u003C18 year-old\n* Patients under legal guardianship, curatorship, or deprived of liberty.\n* Ongoing pregnancy.\n* Patients without social security coverage.","ALL","18 Years",{"count":51,"type":52},50,"ESTIMATED","OBSERVATIONAL","About 10% of patients admitted to the ICU suffer from ARDS, with a mortality rate of around 35-45%. The lack of therapeutic innovation in ARDS can be partly explained by the heterogeneity of patients included under this definition.\n\nA better understanding of the pathophysiological mechanisms underlying the different patient phenotypes is essential to develop new therapeutic strategies.\n\nObjectives:\n\nTo characterize the inflammatory profile of patients with ARDS using circulating biomarkers and single-cell RNA sequencing of pulmonary immune cells.\n\nThe investigators hypothesize that there is a correlation between the profile of serum biomarkers (inflammatory sub-phenotypes), the transcriptome of pulmonary immune cells.\n\nBriefly the experimental scheme is as follow:\n\n* Population: patients with ARDS under invasive mechanical ventilation in the ICU.\n* Intervention:\n\n  1. Determination of the inflammatory subphenotype on circulatory inflammatory biomarkers.\n  2. Characterization of inflammation by single cell RNA sequencing on lung immune cells collected on broncho-alveolar fluid.",[56],"Acute Respiratory Distress Syndrome (ARDS)",[58,59,60],"acute respiratory distress syndrome","subphenotypes","ADRS","2026-05-13",{"date":63,"type":64},"2026-05-14","ACTUAL",{"date":66,"type":64},"2026-05-11",{"date":68,"type":52},"2029-05-11",{"name":5,"class":6},1]